Relay Therapeutics Net Income

Relay Therapeutics (RLAY) currently reports a net income of $-290M as of June 2026. That compares with $-310M in the prior-year period — up 8.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Relay Therapeutics's net income history and peer comparisons.

Relay Therapeutics's net income increased from $-310M to $-290M — a 8.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Relay Therapeutics's net income of $-290M is lower than the Healthcare sector average of $16B. That is roughly 101.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Relay Therapeutics reported $-290M in net income as of June 2026. That compares with $-310M in the prior-year period — up 8.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-290M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Relay Therapeutics, and consider following RLAY for alerts when major investors trade the stock.